The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis - a pooled analysis of five randomised controlled trials

被引:11
|
作者
Manning-Bennett, Arkady T. [1 ]
Hopkins, Ashley M. [2 ]
Sorich, Michael J. [2 ]
Proudman, Susanna M. [3 ,4 ]
Foster, David J. R. [1 ]
Abuhelwa, Ahmad Y. [2 ,5 ]
Wiese, Michael D. [1 ]
机构
[1] Univ South Australia, UniSA Clin & Hlth Sci, North Terrace, Adelaide, SA 5000, Australia
[2] Flinders Univ S Australia, Coll Med & Publ Hlth, Discipline Clin Pharmacol, Bedford Pk, SA, Australia
[3] Royal Adelaide Hosp, Rheumatol Unit, Adelaide, SA, Australia
[4] Univ Adelaide, Discipline Med, Adelaide, SA, Australia
[5] Univ Sharjah, Coll Pharm, Sharjah, U Arab Emirates
关键词
anxiety; depression; Rheumatoid arthritis; remission; tocilizumab; MODIFYING ANTIRHEUMATIC DRUGS; DISEASE-ACTIVITY INDEX; BRITISH ASSOCIATION; AMERICAN-COLLEGE; PREVALENCE; ANTIDEPRESSANTS; TOCILIZUMAB; COMBINATION; DEFINITION; GUIDELINES;
D O I
10.1177/1759720X221111613
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Rheumatoid arthritis (RA) is an inflammatory autoimmune condition associated with an increased risk of developing depression and anxiety. Depression and anxiety are associated with worse outcomes in RA, but the magnitude of the effect of each condition on RA outcomes is unclear. It is also unknown how pharmacological treatment of depression affects RA outcomes. Objective: The primary aim of this study was to investigate the association of comorbid depression and anxiety with remission in patients with RA. Secondary aims were to determine the association between comorbid depression and anxiety on patient-reported outcomes and the relationship between concomitant use of antidepressants and remission in patients with depression. Design: Data from patients with moderate to severe RA were pooled from five randomised controlled trials investigating tocilizumab and conventional synthetic disease-modifying agents. Methods: Remission was defined as a clinical disease activity index (CDAI) of <= 2.8 and simple disease activity index (SDAI) of <= 3.3. The association between the time to reach remission and depression and anxiety was analysed using Cox proportional hazard analysis. Results: Individual patient data were available from 5502 subjects, of whom 511 had depression, 236 had anxiety and 387 were using antidepressants. Depression was significantly associated with reduced remission [adjusted HR (95% CI): 0.62 (0.48-0.80), p < 0.001 and adjusted HR (95% CI): 0.59 (0.44-0.79), p < 0.001] using CDAI and SDAI, respectively. Depression was associated with a lower likelihood of achieving more subjective outcomes (<= 1 physician global assessment, <= 1 patient global assessment) and <= 1 28-swollen joint count, but not <= 1 28-tender joint count or C-reactive protein measurement. Treatment with antidepressants did not improve outcomes for patients with depression. Anxiety was not significantly associated with RA remission. Conclusion: Comorbid depression, but not anxiety, was associated with less frequent remission. Concomitant antidepressant use was not associated with improvements in RA outcomes in patients with depression.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials
    Gustavo Citera
    Rakesh Jain
    Fedra Irazoque
    Hugo Madariaga
    David Gruben
    Lisy Wang
    Lori Stockert
    Karina Santana
    Abbas Ebrahim
    Dario Ponce de Leon
    Rheumatology and Therapy, 2024, 11 : 35 - 50
  • [32] Psychotherapy for the Treatment of Anxiety and Depression in Patients with Parkinson Disease: A Meta-Analysis of Randomized Controlled Trials
    Hong, Chien-Tai
    Tan, Shennie
    Huang, Tsai-Wei
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2021, 22 (11) : 2289 - +
  • [33] Effects of melatonin intake on depression and anxiety in postmenopausal women: a systematic review and meta-analysis of randomised controlled trials
    Kayacik, Ahsen Demirhan
    Ilcioglu, Kevser
    ARCHIVES OF WOMENS MENTAL HEALTH, 2024, 27 (02) : 265 - 273
  • [34] Prevalence for and Factors Associated With Depression and Anxiety Symptoms in Mexican Patients With Rheumatoid Arthritis
    Esther Juarez-Rojop, Isela
    Alberto Nolasco-Rosales, German
    Perez-Mandujano, Antonia
    Beatriz Gonzalez-Castro, Thelma
    Alfonso Tovilla-Zarate, Carlos
    Lilia Lopez-Narvaez, Maria
    Hernandez-Nunez, Eufrates
    Villar-Soto, Mario
    Fresan, Ana
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : S111 - S115
  • [35] Clinical and psychosocial factors associated with depression and anxiety in Singaporean patients with rheumatoid arthritis
    Ho, Roger C. M.
    Fu, Erin H. Y.
    Chua, Anna N. C.
    Cheak, Alicia A. C.
    Mak, Anselm
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2011, 14 (01) : 37 - 47
  • [36] Transdiagnostic internet treatment for anxiety and depression: A randomised controlled trial
    Titov, Nickolai
    Dear, Blake F.
    Schwencke, Genevieve
    Andrews, Gavin
    Johnston, Luke
    Craske, Michelle G.
    McEvoy, Peter
    BEHAVIOUR RESEARCH AND THERAPY, 2011, 49 (08) : 441 - 452
  • [37] The correlations of socioeconomic status, disease activity, quality of life, and depression/anxiety in Chinese patients with rheumatoid arthritis
    Zhang, Lijuan
    Xia, Yunfei
    Zhang, Qiuxiang
    Fu, Ting
    Yin, Rulan
    Guo, Genkai
    Li, Liren
    Gu, Zhifeng
    PSYCHOLOGY HEALTH & MEDICINE, 2017, 22 (01) : 28 - 36
  • [38] Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in PatientsWith Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA
    Abdallah, Hisham
    Hsu, Joy C.
    Lu, Peng
    Fettner, Scott
    Zhang, Xiaoping
    Douglass, Wendy
    Bao, Min
    Rowell, Lucy
    Burmester, Gerd R.
    Kivitz, Alan
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (04) : 459 - 468
  • [39] Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib
    Bird, Paul
    Hall, Stephen
    Nash, Peter
    Connell, Carol A.
    Kwok, Kenneth
    Witcombe, David
    Thirunavukkarasu, Krishan
    RMD OPEN, 2019, 5 (01):
  • [40] A Meta-Analysis of Randomised Placebo-Controlled Treatment Trials for Depression and Anxiety in Parkinson's Disease
    Troeung, Lakkhina
    Egan, Sarah J.
    Gasson, Natalie
    PLOS ONE, 2013, 8 (11):